Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma
10.3779/j.issn.1009-3419.2016.10.06
- VernacularTitle:重组人血管内皮抑制素在晚期肺鳞癌治疗中的临床应用
- Author:
XING PUYUAN
1
;
HAO XUEZHI
;
HU XINGSHENG
;
WANG YAN
;
LI JUNLING
Author Information
1. 国家癌症中心/中国医学科学院北京协和医学院肿瘤医院
- Keywords:
Lung neoplasms;
Squamous cell carcinoma;
Anti-angiogenesis agents;
Recombinant human end-ostatin;
Chemotherapy
- From:
Chinese Journal of Lung Cancer
2016;19(10):670-674
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Squamous cell carcinoma (SCC) is a common pathological type of non-small cell lung cancer, and advanced lung SCC is incurable. Chemotherapy combined with anti-angiogenesis agents can pro-long the patients’ survival time. hTe aim of the study was to analyze the effcacy and safety of recombinant human endostatin (Endostar) in treating advanced lung SCC.Methods We retrospectively analyzed the short-term efficacy and toxicity of recombinant human endostatin combined with traditional chemotherapy regimens in treating 15 advanced lung squamous cell carcinoma patients in Department of Medical Oncology retrospectively, Cancer Hospital, Chinese Academy of Medical Sciences from November 2011 to May 2015. Treatment-related survival was also analyzed.Results Among the evaluble 14 patients, the best overall response was partial response in 5 patients (35.7%), stable disease in 7 patients (50.0%), and progres-sive disease in 2 patients (14.3%). hTe objective response rate (ORR) was 35.7%, and disease control rate (DCR) was 85.7%. hTe median progression-free survival (PFS) was 9.3 months. hTe main grade 3 toxicity was neutropenia (2/15, 13.3%) and vomitting (1/15, 6.7%).Conclusion Chemotherapy combined with recombinant human endostatin enabled good objective response in advanced SCC patients and had well security.
